Biotech and Early Engagement Considerations: What Companies Must Consider When Developing an Asset

Chemistry, Manufacturing, and Controls (CMC)
CMC in Drug Development and Life Cycle Management

This white paper provides biotech companies an overview of the considerations for Chemistry, Manufacturing and Controls (CMC) in asset development. There are a multitude of complexities and points to consider when developing an asset, and product development is at the center of all development. Selection of the right development partner, who has experts in all aspects of CMC, is a critical first step as an asset is developed. The right development partner can ensure there is a consistent ‘end-to-end’ process and continuity in the development of your asset.

In this paper, you will learn about:

CMC Considerations
Why CMC is a critical component in drug development
Why it is important to identify issues early
Why CMOs are critical to success

EBD Group Inc., 3150 Pio Pico Drive, Suite 201, Carlsbad, CA, 92008

Terms and Conditions | Privacy Policy

Country *

First Name *

Last Name *

Email *

Zip Code *

Company Name *

Job Title *

Please tick these boxes if you do not wish to receive marketing information relevant to you from Xconomy

via Email

via Telephone

via Post

Please tick this box if you do not wish to be added to our mailing list for related opportunities from our third party partners

DOWNLOAD NOW: